BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21640920)

  • 1. Cancer immunotherapy.
    White RL; Amin A
    Surg Oncol Clin N Am; 2011 Jul; 20(3):531-54, ix. PubMed ID: 21640920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
    Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
    Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic vaccines for prostate cancer.
    Cha E; Fong L
    Curr Opin Mol Ther; 2010 Feb; 12(1):77-85. PubMed ID: 20140819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-idiotype vaccines for immunotherapy.
    Bhattacharya-Chatterjee M; Chatterjee SK; Foon KA
    Curr Opin Mol Ther; 2001 Feb; 3(1):63-9. PubMed ID: 11249733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cells in cancer immunotherapy.
    Vulink A; Radford KJ; Melief C; Hart DN
    Adv Cancer Res; 2008; 99():363-407. PubMed ID: 18037410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy.
    Schuster M; Nechansky A; Kircheis R
    Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell based cancer vaccines: regulatory and commercial development.
    Copier J; Ward S; Dalgleish A
    Vaccine; 2007 Sep; 25 Suppl 2():B35-46. PubMed ID: 17916462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising immunotherapy technique.
    Fillon M
    J Natl Cancer Inst; 2012 Oct; 104(20):1528-9. PubMed ID: 23044382
    [No Abstract]   [Full Text] [Related]  

  • 13. Design of clinical trials for therapeutic cancer vaccines development.
    Mackiewicz J; Mackiewicz A
    Eur J Pharmacol; 2009 Dec; 625(1-3):84-9. PubMed ID: 19835869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
    Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
    Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in immuno-oncology. Foreword.
    Eggermont A; Finn O
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii5. PubMed ID: 22918929
    [No Abstract]   [Full Text] [Related]  

  • 16. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.
    Cheever MA; Higano CS
    Clin Cancer Res; 2011 Jun; 17(11):3520-6. PubMed ID: 21471425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current status and future perspective of cancer vaccine development].
    Sasada T; Itoh K
    Gan To Kagaku Ryoho; 2011 Apr; 38(4):503-8. PubMed ID: 21498975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.
    Gulley JL; Madan RA; Heery CR
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future of immunotherapy drug combinations and biomarkers.
    Schmidt C
    J Natl Cancer Inst; 2012 Mar; 104(6):434-9. PubMed ID: 22402694
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic cancer vaccine development: will it ride the wave of new immunomodulatory agents?
    Eggermont AM
    Cancer J; 2011; 17(5):276. PubMed ID: 21952275
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.